Iceland· IS-EU/1/07/419/004-009
Cervarix
A humaner papillomvirus (typen 16, 18) product containing mannapapillomaveira af gerð 16 l1 prótein,mannapapillomaveira af gerð 18 l1 prótein, registered in Iceland by GlaxoSmithKline Biologicals S.A.*. The same ATC class is registered in 10 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Humaner papillomvirus (typen 16, 18) is registered in 10 of 19 countries.
Countries holding a registration under ATC J07BM02 (humaner papillomvirus (typen 16, 18)), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 6 of them publish a price we can compare per daily dose
Humaner papillomvirus (typen 16, 18) · ATC J07BM02
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Mannapapillomaveira af gerð 16 L1 prótein,Mannapapillomaveira af gerð 18 L1 prótein
- Manufacturer
- GlaxoSmithKline Biologicals S.A.*
- Country
- Iceland (IS)
- ATC code
- J07BM02
- ATC class
- Humaner Papillomvirus (Typen 16, 18)
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07BM02
Humaner papillomvirus (typen 16, 18), as other registers publish it.
- IcelandCervarixGlaxoSmithKline Biologicals S.A.*
- PolandCervarixGlaxoSmithKline Biologicals S.A.
- BelgiumCervarixGlaxoSmithKline Biologicals
- FinlandCervarixGlaxoSmithKline Biologicals SA
- PolandCervarixGlaxoSmithKline Biologicals S.A.
- IcelandCervarixGlaxoSmithKline Biologicals S.A.*
- BelgiumCervarixGlaxoSmithKline Biologicals
- DenmarkCervarixGlaxoSmithKline Biologicals S.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f361c8bc-30d7-4b14-8bb4-460584aab2f0 GET /v1/drugs/f361c8bc-30d7-4b14-8bb4-460584aab2f0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, dreifa í áfylltri sprautu",
"source": "lyfjastofnun",
"atc_raw": "J07BM02",
"marketed": false,
"strength": null,
"ma_number": "EU/1/07/419/004-009",
"substance": "Mannapapillomaveira af gerð 16 L1 prótein,Mannapapillomaveira af gerð 18 L1 prótein",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "39345"
}See everything about humaner papillomvirus (typen 16, 18).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.